NHL & CLL - Diagnosis and Treatment Update

A Live Telephone/Web Education Program Offering Spanish & Portuguese Interpretation Featuring Expert Christopher R. Flowers, MD, MS

WHITE PLAINS, N.Y., Aug. 23, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish- and Portuguese-speaking patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) and their families. On Thursday, September 13 from 1:00 to 2:30 PM Eastern Time, Dr. Christopher R. Flowers from the Winship Cancer Institute of Emory University, will present a free, live telephone/web education program titled NHL & CLL–Diagnosis and Treatment Update. This program will be presented simultaneously in Spanish and Portuguese.

Each year, approximately 66,000 people are diagnosed with NHL and 14,500 people are diagnosed with CLL. In the last several years, new NHL and CLL therapies have been developed and FDA-approved, and  more promising therapies are currently being studied in clinical trials. During the program on September 13, Dr. Flowers will discuss NHL and CLL diagnosis, current and emerging treatment options and side effects management. This program, offered by The Leukemia & Lymphoma Society, is supported by a grant from Genentech and Biogen Idec and is presented in collaboration with Abrale and Alianza Latina. Continuing education credit is available for nurses and social workers.

To register for the September 13 program NHL & CLL–Diagnosis and Treatment Update in Spanish, please visit www.LLS.org/NHL-CLLsp.

To register for NHL & CLL–Diagnosis and Treatment Update in Portuguese, please visit www.LLS.org/NHL-CLLpg.

To register for NHL & CLL–Diagnosis and Treatment Update in English, please visit www.LLS.org/programs.

For information on other LLS programs, please visit www.LLS.org/programs or contact an Information Specialist at (800) 955-4572.

SOURCE The Leukemia & Lymphoma Society

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.